# SARON: HCP commentary report

> 156 verified HCP statements from 30 commentary sources · 9 findings · updated Oct 17, 2026

## Report

- Trial: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase II Trial
- NCT ID: NCT02417662
- Registry: https://clinicaltrials.gov/study/NCT02417662
- Sponsor: University College, London
- Phase: Not applicable
- Status: Active, not recruiting
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-17
- Last checked: 2026-10-17
- Release hash: 911047668840ae30a75a252a0bf17dc0abb146955e0e65c13bd55ebc62da1232

## Counts

- HCP commentary sources screened: 41
- Sources cited by verified HCP statements: 30
- Verified HCP statements: 156
- Findings: 9
- People found in screened sources: 41
- People identity-verified: 40
- Voices cited: 44

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

SARON asks whether adding radical radiotherapy to systemic treatment helps patients with synchronous oligometastatic non-small cell lung cancer. Clinicians discuss patient selection, disease at diagnosis versus limited residual disease after induction, and comparisons with related randomized studies. Other topics include systemic-treatment era and sequencing, treatment of the lung primary, local treatment options, safety, patient-relevant endpoints, and potential implications for practice. SARON's main results are scheduled for ESMO 2026; this report reflects commentary before that presentation.

## Open Medical Affairs question

Which baseline disease states and post-induction patterns must be distinguished before discussing the applicability of SARON?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A negative local-therapy study was not interpreted uniformly as a verdict on synchronous oligometastatic disease
- F2. Selection concerns extend beyond lesion count to biology, disease tempo and real-world applicability
- F3. Completeness of local treatment matters to clinicians, but the supporting observations require careful separation
- F4. Treating the primary: advocacy, modality choices and limits of acute-safety reassurance
- F6. Systemic-treatment era and the intended role of local therapy remain central uncertainties
- F7. The endpoint debate is about meaningful added value, not simply whether PFS can improve
- F8. The LU002 progression threshold prompted a specific, unresolved statistical-design disagreement
- F9. Enthusiasm for local therapy was paired with equipoise, recruitment and evidence-completeness concerns
- F10. SARON was repeatedly positioned as important forthcoming evidence, not as a known positive or negative result

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 11 | 10 | 2 | 4 | recorded | 3 |
| F2 | 10 | 9 | 6 | 7 | recorded | 2 |
| F3 | 5 | 5 | 4 | 4 | recorded | 3 |
| F4 | 10 | 10 | 6 | 7 | recorded | 6 |
| F6 | 8 | 6 | 6 | 5 | recorded | 3 |
| F7 | 8 | 9 | 3 | 6 | recorded | 3 |
| F8 | 7 | 7 | 2 | 4 | recorded | 3 |
| F9 | 11 | 11 | 4 | 7 | recorded | 3 |
| F10 | 14 | 13 | 10 | 10 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 4 | 0 | 3 | 0 | 11 | 5 | 1 post or article, 1 podcast or video | yes |
| F2 | 3 | 4 | 1 | 2 | 0 | 10 | 0 | 6 posts and articles | yes |
| F3 | 3 | 0 | 0 | 0 | 2 | 6 | 0 | 3 posts and articles, 1 podcast or video | yes |
| F4 | 5 | 1 | 1 | 1 | 2 | 10 | 3 | 5 posts and articles, 1 podcast or video | yes |
| F6 | 2 | 4 | 0 | 2 | 0 | 8 | 0 | 6 posts and articles | yes |
| F7 | 2 | 3 | 0 | 2 | 1 | 8 | 1 | 2 posts and articles, 1 podcast or video | yes |
| F8 | 2 | 3 | 0 | 1 | 1 | 8 | 0 | 2 posts and articles | yes |
| F9 | 7 | 2 | 0 | 1 | 1 | 11 | 0 | 4 posts and articles | yes |
| F10 | 6 | 2 | 1 | 0 | 5 | 14 | 0 | 10 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Overall Survival: F1 (1 shared claims), F6 (1 shared claims), F7 (1 shared claims)
- Secondary endpoints: F1 (1 shared claims), F4 (3 shared claims), F7 (8 shared claims), F8 (1 shared claims)
- Population and setting: F1 (7 shared claims), F2 (9 shared claims), F4 (2 shared claims), F6 (2 shared claims)
- The comparison: F1 (3 shared claims), F3 (4 shared claims), F4 (7 shared claims), F6 (6 shared claims)
- Safety and tolerability: F2 (2 shared claims), F4 (4 shared claims)
- Design and conduct: F6 (1 shared claims), F8 (7 shared claims), F9 (8 shared claims), F10 (9 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. A negative local-therapy study was not interpreted uniformly as a verdict on synchronous oligometastatic disease

A podcast speaker asked whether clinicians should continue treatment directed at oligometastatic disease or pause it while awaiting SARON results, in light of related trial evidence.

Source: podcast, 2024-06-19.

### F6. Systemic-treatment era and the intended role of local therapy remain central uncertainties

An X-thread participant asked whether SARON's findings might differ from related randomized evidence in the context of changing systemic treatment.

Source: X thread, 2024-06-02.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified HCP statements with short source quotes and links | 156 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 30 | Counts free |
| Speaker attribution for cited voices | 44 | Paid |

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival | discussed | 8 | 5 |
| Secondary endpoints | discussed | 13 | 7 |
| Population and setting | discussed | 25 | 11 |
| The comparison | discussed | 28 | 12 |
| Safety and tolerability | discussed | 6 | 5 |
| Design and conduct | discussed | 31 | 13 |
| Biological selection, disease tempo and generalizability | discussed | 18 | 8 |
| Completeness of treatment, staging and lesion-level coverage | discussed | 11 | 6 |
| Systemic-treatment era, sequencing and repeated local intervention | discussed | 15 | 9 |
| Clinical uptake, equipoise and access to comparative evidence | discussed | 23 | 11 |
| Interpretation of incomplete results and anticipated SARON impact | discussed | 24 | 13 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 34 | 28 |
| Podcasts | 4 | 2 |
| YouTube | 3 | 0 |

- Screened window: 2019-04-14 to 2026-10-06
- Cited window: 2019-04-14 to 2026-09-26
- Retrieved: 2026-10-17

Screened sources were retrieved for this trial. Cited sources back at least one verified HCP statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase II Trial
- Registry: NCT02417662 (https://clinicaltrials.gov/study/NCT02417662)
- Study IDs: UCL/13/0594
- Sponsor: University College, London
- Collaborators: Cancer Research UK
- Design: Not applicable · interventional, randomized, parallel, na
- Status: Active, not recruiting
- Enrollment: 140 (actual)
- Start: 2016-08-19 (actual)
- Primary completion: 2026-09 (estimated)
- Primary endpoint: Overall Survival (From date of randomisation to the date of death, up to 36 months)
- Intervention: Radical Radiotherapy (Conventional RT and SABR) (radiation)
- Intervention: Non-investigational SACT (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 1 passage in the reviewed sources discusses other trials or topics outside this report's scope; it is not part of this edition.
- 12 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are not a representative sample of HCP opinion; neither source numbers nor repeated posts establish consensus.
- Some potentially relevant posts and videos were unavailable, and searching mainly by trial names and identifiers may have missed unnamed or differently transcribed references.
- Some passages may not have been fully assessed, so additional relevant qualifications or views may be absent.
- Two comments relaying someone else's talk did not identify whose positions were being conveyed and cannot support attribution to a named clinician.
- Several numerical study descriptions and results are clinicians' accounts of related trials, not independent extractions from complete trial reports.
- The main SARON efficacy-results publication is not among the sources reviewed; anticipated effects on practice are expectations rather than observed implementation.
- Anonymous panel responses are not assigned to people on a program or guest list. Professional credentials and identity confirmation are not equally available for all named authors.
- Posts from different dates, settings or identically named accounts are not used to infer a change of mind or a longitudinal disagreement.
- The two SARON thoracic sub-study safety posts use different severe-toxicity thresholds and do not establish late or whole-trial safety.
- A full SARON protocol was not available in the reviewed material, limiting independent assessment of commentators' population and treatment comparisons.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-17: current edition

Last checked for new commentary 2026-10-17. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (156 verified HCP statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (40 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/saron-nct02417662
- Agents: POST https://www.erudio.com/api/orders with {"report": "saron-nct02417662", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=saron-02417662

## Cite

Erudio Health. SARON (NCT02417662): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 17, 2026. https://www.erudio.com/reports/saron-nct02417662

## Machine access

- JSON: https://www.erudio.com/reports/saron-nct02417662.json
- Markdown: https://www.erudio.com/reports/saron-nct02417662.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "saron-02417662"}`